Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Raw Materials (2016 - 2024)

Historic Raw Materials for Astrazeneca (AZNCF) over the last 10 years, with Q4 2024 value amounting to $1.5 billion.

  • Astrazeneca's Raw Materials fell 274.33% to $1.5 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $1.5 billion, marking a year-over-year decrease of 274.33%. This contributed to the annual value of $1.5 billion for FY2024, which is 274.33% down from last year.
  • Latest data reveals that Astrazeneca reported Raw Materials of $1.5 billion as of Q4 2024, which was down 274.33% from $1.5 billion recorded in Q4 2023.
  • Astrazeneca's 5-year Raw Materials high stood at $1.8 billion for Q4 2021, and its period low was $1.3 billion during Q4 2020.
  • Moreover, its 5-year median value for Raw Materials was $1.5 billion (2024), whereas its average is $1.5 billion.
  • As far as peak fluctuations go, Astrazeneca's Raw Materials surged by 5204.82% in 2020, and later crashed by 1897.44% in 2022.
  • Over the past 5 years, Astrazeneca's Raw Materials (Quarter) stood at $1.3 billion in 2020, then skyrocketed by 39.06% to $1.8 billion in 2021, then dropped by 18.97% to $1.4 billion in 2022, then increased by 7.67% to $1.5 billion in 2023, then dropped by 2.74% to $1.5 billion in 2024.
  • Its Raw Materials was $1.5 billion in Q4 2024, compared to $1.5 billion in Q4 2023 and $1.4 billion in Q4 2022.